Phase II, open label REJUVENATE study of the pharmacokinetics and safety of aztreonam avibactam plus metronidazole in hospitalised adults with complicated intra abdominal infection
Download publication
Related media library items
08/10/2024
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
Background There is a need for additional therapeutic options for serious infections caused by Gram-negative pathogens. In the phase 3, descriptive R...
19/06/2024
International and regional spread ofcarbapenem-resistant Klebsiella pneumoniae in Europe
Abstract Carbapenem-resistant Klebsiella pneumoniae (CRKP) are of particular concern due to the spread of antibiotic resistance genes associated with ...
01/06/2023
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Data support that antibiotic aztreonam -avibactam (ATM-AVI) is effective and well- tolerated in treating infections caused by Gram-negative bacteri...